A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia
about
Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor AntagonismEffects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality DisorderPharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.Investigational drugs for schizophrenia targeting the dopamine receptor: phase II trials.Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development.Dopamine receptor homooligomers and heterooligomers in schizophreniaModeling "psychosis" in vitro by inducing disordered neuronal network activity in cortical brain slices.The treatment of cognitive impairment in schizophrenia.Can genetics inform the management of cognitive deficits in schizophrenia?Dopamine receptor signaling and current and future antipsychotic drugs.Pharmacotherapy of cognitive deficits in schizophrenia.Pharmacological Interventions for the MATRICS Cognitive Domains in Schizophrenia: What's the Evidence?Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.Emerging drugs for schizophrenia: an update.Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia.Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward.Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia.Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride.A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia.Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience.Dopamine D1 receptor subtype mediates acute stress-induced dendritic growth in excitatory neurons of the medial prefrontal cortex and contributes to suppression of stress susceptibility in mice.Interaction of childhood urbanicity and variation in dopamine genes alters adult prefrontal function as measured by functional magnetic resonance imaging (fMRI).
P2860
Q28084069-7094B239-4421-4BDD-88B6-E164ECA70EA2Q29038503-496B4ADD-7E36-4BD5-BBB9-14E62468B698Q34274859-B4295192-7DC4-4A72-B309-424327FAE401Q34703195-B0FCE875-0875-4003-B18E-54B5030F9E3CQ36886717-2CE5947C-25D1-4492-A851-191B838EDB26Q36930839-9119E12F-F1F7-4071-A4C8-858BAB6617A1Q36935148-31CAABA0-5B5F-4CC4-BD14-43BD5F1DB772Q37242424-6C9AFDFE-14EE-4846-BAC9-B5A1315DAFE8Q37400709-6BDD2DC9-8182-4ACD-8098-5F39E364B07BQ37813206-593A2799-F530-4A3E-B40B-77A6AAC6E8D3Q37983548-6427C452-B26B-40E9-AB59-DA97B7D82FB9Q38058009-11432AB5-9BE8-424F-B72F-117361110544Q38162531-5A1EEC7D-6F58-4603-9368-69805D8B1AADQ38173359-5798347A-731E-423B-B3A9-3BBAE85FC023Q38187948-A9369687-5A5B-47E1-88A3-CC37BD69AB83Q38252404-D3295600-FAD1-4181-AAB4-250977181EF2Q38762256-EB56B5D2-D128-4C97-96EC-2FE6B790A346Q39062177-83375507-1407-41B4-AC09-A17AFF1BA346Q42367850-CB238A61-CE8E-4A8D-8A71-8ADCBAD94334Q42652786-EB747A14-889B-47A8-9024-1A451E078BCAQ46330442-B9D29159-2E82-46AE-931D-1EC40BEB3389Q47550545-2B1D5A35-DB97-4D02-B500-8A73E97B2AF0Q47619041-A18C032A-FD88-4865-A102-D0B15765F653Q55378329-9FA2A3DB-3D3D-4CF5-A01D-DD78763E8DA7
P2860
A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia
description
2007 nî lūn-bûn
@nan
2007 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A single 20 mg dose of dihydre ...... in patients with schizophrenia
@ast
A single 20 mg dose of dihydre ...... in patients with schizophrenia
@en
A single 20 mg dose of dihydre ...... in patients with schizophrenia
@nl
type
label
A single 20 mg dose of dihydre ...... in patients with schizophrenia
@ast
A single 20 mg dose of dihydre ...... in patients with schizophrenia
@en
A single 20 mg dose of dihydre ...... in patients with schizophrenia
@nl
prefLabel
A single 20 mg dose of dihydre ...... in patients with schizophrenia
@ast
A single 20 mg dose of dihydre ...... in patients with schizophrenia
@en
A single 20 mg dose of dihydre ...... in patients with schizophrenia
@nl
P2093
P1476
A single 20 mg dose of dihydre ...... in patients with schizophrenia
@en
P2093
Berry Anderson
Christine E Molnar
David E Nichols
Emily L Grenesko
Jorge Juncos
Kevin Johnson
Mark S George
Michael Knable
Prabhavathi Fernandes
P356
10.1016/J.SCHRES.2007.03.011
P407
P577
2007-07-01T00:00:00Z